FY2025 EPS Estimate for Sanara MedTech Decreased by Analyst

Sanara MedTech Inc. (NASDAQ:SMTI) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Sanara MedTech in a research report issued to clients and investors on Wednesday, March 26th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of ($2.43) for the year, down from their prior forecast of ($0.98). Cantor Fitzgerald has a “Overweight” rating and a $46.00 price target on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Separately, HC Wainwright upped their price objective on Sanara MedTech from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday.

Sanara MedTech Price Performance

Shares of NASDAQ:SMTI opened at $30.19 on Friday. Sanara MedTech has a one year low of $26.00 and a one year high of $39.08. The stock has a market capitalization of $263.89 million, a price-to-earnings ratio of -30.49 and a beta of 1.37. The company has a 50-day simple moving average of $34.26 and a 200-day simple moving average of $33.74. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23.

Sanara MedTech (NASDAQ:SMTI) last announced its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The business had revenue of $26.31 million for the quarter, compared to analyst estimates of $22.75 million.

Institutional Trading of Sanara MedTech

Several hedge funds have recently made changes to their positions in SMTI. Fifth Third Bancorp purchased a new stake in Sanara MedTech in the 4th quarter valued at approximately $898,000. Barclays PLC boosted its stake in shares of Sanara MedTech by 323.0% in the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock valued at $174,000 after buying an additional 4,376 shares in the last quarter. Geode Capital Management LLC grew its holdings in Sanara MedTech by 4.4% during the third quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after acquiring an additional 3,755 shares during the period. State Street Corp raised its position in Sanara MedTech by 9.2% in the third quarter. State Street Corp now owns 58,688 shares of the company’s stock worth $1,775,000 after acquiring an additional 4,932 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Sanara MedTech by 127.2% in the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock valued at $123,000 after acquiring an additional 2,272 shares during the period. Institutional investors and hedge funds own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.